| ||||||||||||||||
| ||||||||||||||||
— Eli Lilly —Top tagsYou have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "Eli Lilly." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.
Community
 Entries tagged "Eli Lilly"The marriage of theory and practiceAbigail Barrow and Steven Shapin on the interaction of science, technology and economic development. Dialoguing at DeutscheBruce Evans takes the reins of Deutsche's M&A effort at a difficult time. The big trialFrom VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Cravath helps Bristol feed a starved IPO marketBristol-Myers plans to raise $500M-plus selling shares in Mead Johnson Nutrition Co. Cravath's Ronald Cami and Susan Webster are advising. Out of rhythmBoston Scientific snatched cardiac implant maker Guidant away from healthcare giant Johnson & Johnson three years ago and hasn't breathed easily since. Winter's chillLaw firms struggle to cope with deal markets that have gone deathly quiet. The comparison: Silicon Valley after the dot-com bust. Where dealmaking is healthyVeteran healthcare dealmakers are moving to smaller firms, including Samantha Miller, who joined Jennerex Biotherapeutics. They need a new drugExpect Big Pharma to go shopping in biotechland, but with an eye for fire sales. Lilly and Latham join forces againGibson Dunn's Anne Benedict advised United Therapeutics in its deal with Eli Lilly. ImCloneMassachusetts' State-Boston Pension Fund has stepped in with a lawsuit to block Eli Lilly's $6.5 billion deal for ImClone. Spread too farAmid turmoil, risk arbs have absorbed a lot of bad news, but some strategic deals look likely to close, and deal demand may be building. Latham gilds Lilly's ImClone offerDeutsche Bank AG's Jim Stynes, Michael Cohen and Bruce Evans were among the financial advisers. Litigation riskFASB weighs requiring companies to estimate their exposure to legal damages; business tries to bury the idea. | ||||||||||||||||
|
|
|
|
|
